Personalized attack on Tough-to-Treat gynecologic cancers
NCT ID NCT04065269
Summary
This trial is testing new drug combinations for women whose gynecologic cancers (like ovarian or uterine cancer) have returned after previous treatment. It aims to see if matching specific drug combinations to a patient's cancer type and a particular gene change (called ARID1A) can help control the disease. The study is for patients whose cancer has progressed after at least one prior platinum-based chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNAECOLOGICAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College NHS Trust
London, United Kingdom
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Royal United Hospital
Bath, BA1 3NG, United Kingdom
-
The Beatson
Glasgow, United Kingdom
-
The Christie
Manchester, United Kingdom
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
University of Montreal Hospital Centre
Montreal, Quebec, H2X 3E4, Canada
-
Western General Hospital
Edinburgh, United Kingdom
Conditions
Explore the condition pages connected to this study.